Slide 1: Third Quarter 2014 Earnings Presentation
Exhibit 1 Third Quarter 2014 Earnings Presentation November 10, 2014
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects," "believes," “plans,” “scheduled," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and u
Slide 3: Pipeline
LEAD DEVELOPMENT PROGRAMS BL-8040 BL-7010 AML ‘Stem cell mobilization Celiac disease ADDITIONAL DEVELOPMENT PROGRAMS BL-5010 BL-7040 BL-9010 BL-1110 PROGRAMS PARTNERED OR IN CO-DEVELOPMENT BL-1040 BL-8020 BL-8030 BL-9020 Ventricular remodeling post-AMI HCV and other viral indications HCV TED, ©212bo
Slide 4: Update on Operations and Lead Programs
Chief Executive Officer Kinneret Savitsky, Ph.D. Update on Operations and Lead Programs 4
Slide 5: BL-8040: Best-in-Class CXCR4 Antagonist
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST Promising Platform for AML and Other Hematological Indications ü Robust apoptosis of cancer cells ü Substantial mobilization of cancer cells from bone marrow ü Synergizes with other AML treatments ü Strong global IP estate: 13 issued/25 patents pending worldwi
Slide 6: BL-8040: Acute Myeloid Leukemia (AML)
BL-8040: Acute Myeloid Leukemia (AML) Current Status - Completing Phase 2 dose escalation stage ü Dec. 2013: Announced promising partial dose escalation phase results ü Nov. 2014: Increased dosing based on encouraging efficacy and excellent safety • Unanimous recommendation by Clinical Advisory Boar
Slide 7: BL-8040: Continued
BL-8040: CONTINUED Stem Cell Mobilization ü Jun. 2014: Received approval from Israeli Ministry of Health to begin human studies ü Sep. 2014: Initiated two-part Phase 1 study Part 1: Safety and tolerability as a standalone therapy • Dose escalation (randomized, double-blind, placebo-controlled); 32 v
Slide 8: BL-7010: Novel Gliadin Binding Polymer for Celiac Disease
BL-7010: NOVEL GLIADIN BINDING POLYMER FOR CELIAC DISEASE Exciting progress in a fast-growing market – Significantly increased Pharma interest – Very high-need and underserved population Phase 1/2 study completed in celiac patients: ü Mar. 2014: Completed dose escalation stage; initiated repeated-do
Slide 9: BL-1040: First-in-Class Bioabsorbable Cardiac Matrix
BL-1040: FIRST-IN-CLASS BIOABSORABLE CARDIAC MATRIX FOR PREVENTION OF VENTRICULAR REMODELING FOLLOWING AMI • Pivotal CE Mark registration trial continues on schedule – Trial enrolled >280 patients of ~300 patients – Endpoints: End diastolic volume index, QLQ, six-minute walk test • Still expect to c
Slide 10: Third Quarter 2014 Financial Overview
Chief Financial & Operating Officer Philip A. Serlin, CPA, MBA Third Quarter 2014 Financial Overview 10
Slide 11: Corporate Highlights
Corporate Highlights • Strong current cash position: $29.6 million at September 30, 2014 • Funds operational capital through end of 2016 • Expect to reach several value inflection points during this time • Broad U.S. institutional investor base • U.S. investors hold roughly 60% of total shares outst
Slide 12: Financial Overview
Financial Overview (in USD at 30-Sep-14 exchange rate) • Research and development • Total R&D expenses decreased by $4.4 million, to $8.0 million for the nine months ended September 30, 2014 • Primarily from termination of the BL-1020 CLARITY clinical trial in March 2013, as well as certain one-time
Slide 13: Financial Overview
Financial Overview (in USD at 30-Sep-14 exchange rate) • General and administrative • G&A expenses decreased by $0.2 million, to $2.5 million for the nine months ended September 30, 2014 • Primarily due to a one-time expense for professional services in the 2013 period • Non-operating income • Non-o
Slide 14: Major Development Milestones - 2014 and 2015
Major Development Milestones - 2014 and 2015 BL-9020 (Type 1 Diabetes) collaboration with JHL √ BL-7010 (Celiac Disease) phase 1/2 study update* √ BL-8040 (SC Mobilization) phase 1 initiation √ BL-7010 (Celiac Disease) phase 1/2 completion √ BL-1040 (AMI) complete CE mark study enrollment BL-8040 (A
Slide 15: Thank You! Questions?
BenAto Bedsideo Padner > =~ ‘ THANK YOU! QUESTIONS? BIOLINEM ><